Needham Reiterates Buy on Bicycle Therapeutics, Maintains $46 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Bicycle Therapeutics (NASDAQ:BCYC) and maintained a price target of $46.
September 12, 2023 | 9:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Bicycle Therapeutics and maintained a price target of $46, indicating a positive outlook for the company.
The reiteration of a 'Buy' rating by a Needham analyst indicates a positive outlook for Bicycle Therapeutics. The maintained price target of $46 suggests that the analyst believes the company's stock is undervalued, which could lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100